All of our programs are first-in-class and internally generated, each representing an opportunity to make a transformational impact across numerous diseases with high unmet need.
POC=proof-of-concept.
IND=investigational new drug.
sHLH=secondary hemophagocytic lymphohistiocytosis.
TCL=T cell lymphoma.
T-ALL=T cell acute lymphoblastic leukemia.
POC=proof-of-concept.
IND=investigational new drug.
sHLH=secondary hemophagocytic lymphohistiocytosis.
TCL=T cell lymphoma.
T-ALL=T cell acute lymphoblastic leukemia.
© 2024 Electra Therapeutics Inc.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |